Sanofi reviews consumer health business media buying and planning account post-Boehringer swap

Sanofi's headquarters in Paris
Sanofi is taking a look at its consumer media buying and planning account, just months after its Boehringer Ingelheim asset swap finalized.

Sanofi is reportedly putting its consumer healthcare media buying account into play following the completion of a trade for Boehringer Ingelheim's consumer assets. The asset swap deal, sealed in January, exchanged Sanofi's animal health unit Merial with BI's consumer health portfolio.

The consumer media review, reported first by Campaign, puts Sanofi’s estimated €900 million media buying and planning account on the market. The account is currently held by Publicis Media's Zenith and former BI agency WPP Group M, although Sanofi is reportedly open to solutions and may not force a consolidation, according to Campaign.

The beefed up Sanofi OTC division is part of new CEO Olivier Brandicourt’s plan to remake the drugmaker into a leader in consumer healthcare as its diabetes business declines. Sanofi OTC brands include Allegra, Nasacort and Maalox, while the newly added BI brands count Ducolax and global antispasmodic Buscopan among them.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

When the deal was announced, industry watchers estimated that BI’s assets would give Sanofi a 4.6% share of the global consumer health market, ranking sixth in the U.S. But the French company still has some formidable foes to deal with in the OTC department, including the market-leading GlaxoSmithKline-Novartis joint venture.

Sanofi did not respond to a request for comment on the review.

Suggested Articles

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

When AstraZeneca sold its Avlon, England plant in 2016, it thought its liabilities were over. Former employees said the drugmaker broke its promises.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps.